Binding Site Information of Target
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T51499 | Target Info | |||
Target Name | Ganglioside GM2 activator (GM2A) | ||||
Synonyms | Sphingolipid activator protein 3; SAP3; Ganglioside GM2 activator isoform short; GM2AP; GM2A; Cerebroside sulfate activator protein | ||||
Target Type | Clinical trial Target | ||||
Gene Name | GM2A | ||||
UniProt ID |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: Oleic acid | Ligand Info | |||||
Structure Description | Crystal Structure Analysis of GM2-activator protein complexed with phosphatidylcholine | PDB:2AG4 | ||||
Method | X-ray diffraction | Resolution | 1.80 Å | Mutation | No | [1] |
PDB Sequence |
HMSSFSWDNC
10 DEGKDPAVIR20 SLTLEPDPIV30 VPGNVTLSVV40 GSTSVPLSSP50 LKVDLVLEKE 60 VAGLWIKIPC70 TDYIGSCTFE80 HFCDVLDMLI90 PTGEPCPEPL100 RTYGLPCHCP 110 FKEGTYSLPK120 SEFVVPDLEL130 PSWLTTGNYR140 IESVLSSSGK150 RLGCIKIAAS 160 LKGI
|
|||||
|
||||||
Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
Ligand Name: Lauric acid | Ligand Info | |||||
Structure Description | Crystal Structure analysis of GM2-Activator protein complexed with phosphatidylcholine | PDB:2AF9 | ||||
Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | No | [1] |
PDB Sequence |
MSSFSWDNCD
9 EGKDPAVIRS19 LTLEPDPIVV29 PGNVTLSVVG39 STSVPLSSPL49 KVDLVLEKEV 59 AGLWIKIPCT69 DYIGSCTFEH79 FCDVLDMLIP89 TGEPCPEPLR99 TYGLPCHCPF 109 KEGTYSLPKS119 EFVVPDLELP129 SWLTTGNYRI139 ESVLSSSGKR149 LGCIKIAASL 159 KGI
|
|||||
|
LEU45
3.872
LEU49
3.870
VAL51
3.461
LEU53
3.965
LEU55
4.279
LYS57
3.511
ILE66
4.456
PHE80
3.186
PHE109
3.072
LEU132
3.035
THR133
4.533
TYR137
3.146
|
|||||
Ligand Name: Lpc-Ether | Ligand Info | |||||
Structure Description | Human GM2 Activator Protein PAF complex | PDB:1TJJ | ||||
Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | No | [2] |
PDB Sequence |
HMSSFSWDNC
10 DEGKDPAVIR20 SLTLEPDPIV30 VPGNVTLSVV40 GSTSVPLSSP50 LKVDLVLEKE 60 VAGLWIKIPC70 TDYIGSCTFE80 HFCDVLDMLI90 PTGEPCPEPL100 RTYGLPCHCP 110 FKEGTYSLPK120 SEFVVPDLEL130 PSWLTTGNYR140 IESVLSSSGK150 RLGCIKIAAS 160 LKGI
|
|||||
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .LPE or .LPE2 or .LPE3 or :3LPE;style chemicals stick;color identity;select .A:17 or .A:18 or .A:19 or .A:41 or .A:42 or .A:43 or .A:47 or .A:53 or .A:55 or .A:73 or .A:79 or .A:82 or .A:85 or .A:86 or .A:89 or .A:90 or .A:100 or .A:106 or .A:107 or .A:111 or .A:116 or .A:143 or .A:144 or .A:145 or .A:153 or .A:154 or .A:155; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
ALA17
3.696
VAL18
3.435
ILE19
3.743
GLY41
3.939
SER42
3.952
THR43
4.239
LEU47
4.126
VAL53
3.431
LEU55
3.762
TYR73
4.641
PHE79
3.984
PHE82
3.566
VAL85
4.580
LEU86
3.718
|
|||||
Ligand Name: Myristic acid | Ligand Info | |||||
Structure Description | Crystal Structure analysis of GM2-Activator protein complexed with phosphatidylcholine | PDB:2AF9 | ||||
Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | No | [1] |
PDB Sequence |
MSSFSWDNCD
9 EGKDPAVIRS19 LTLEPDPIVV29 PGNVTLSVVG39 STSVPLSSPL49 KVDLVLEKEV 59 AGLWIKIPCT69 DYIGSCTFEH79 FCDVLDMLIP89 TGEPCPEPLR99 TYGLPCHCPF 109 KEGTYSLPKS119 EFVVPDLELP129 SWLTTGNYRI139 ESVLSSSGKR149 LGCIKIAASL 159 KGI
|
|||||
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .MYR or .MYR2 or .MYR3 or :3MYR;style chemicals stick;color identity;select .A:22 or .A:27 or .A:29 or .A:33 or .A:35 or .A:121 or .A:123 or .A:124 or .A:125 or .A:126 or .A:128 or .A:133 or .A:159; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
Ligand Name: PAF | Ligand Info | |||||
Structure Description | Human GM2 Activator Protein PAF complex | PDB:1TJJ | ||||
Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | No | [2] |
PDB Sequence |
HMSSFSWDNC
10 DEGKDPAVIR20 SLTLEPDPIV30 VPGNVTLSVV40 GSTSVPLSSP50 LKVDLVLEKE 60 VAGLWIKIPC70 TDYIGSCTFE80 HFCDVLDMLI90 PTGEPCPEPL100 RTYGLPCHCP 110 FKEGTYSLPK120 SEFVVPDLEL130 PSWLTTGNYR140 IESVLSSSGK150 RLGCIKIAAS 160 LKGI
|
|||||
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .PFS or .PFS2 or .PFS3 or :3PFS;style chemicals stick;color identity;select .A:19 or .A:22 or .A:24 or .A:29 or .A:37 or .A:39 or .A:40 or .A:41 or .A:57 or .A:68 or .A:74 or .A:105 or .A:116 or .A:117 or .A:118 or .A:128 or .A:130 or .A:139 or .A:140 or .A:141 or .A:155 or .A:157 or .A:158 or .A:159 or .A:161; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
ILE19
3.596
LEU22
4.124
LEU24
3.577
ILE29
4.926
LEU37
4.070
VAL39
3.231
VAL40
4.580
GLY41
4.252
LEU57
2.904
ILE68
3.594
ILE74
4.473
LEU105
4.122
TYR116
3.271
|
|||||
Ligand Name: 1-Stearoyl-sn-glycero-3-phosphocholine | Ligand Info | |||||
Structure Description | Crystal Structure Analysis of GM2-activator protein complexed with phosphatidylcholine | PDB:2AG4 | ||||
Method | X-ray diffraction | Resolution | 1.80 Å | Mutation | No | [1] |
PDB Sequence |
HMSSFSWDNC
10 DEGKDPAVIR20 SLTLEPDPIV30 VPGNVTLSVV40 GSTSVPLSSP50 LKVDLVLEKE 60 VAGLWIKIPC70 TDYIGSCTFE80 HFCDVLDMLI90 PTGEPCPEPL100 RTYGLPCHCP 110 FKEGTYSLPK120 SEFVVPDLEL130 PSWLTTGNYR140 IESVLSSSGK150 RLGCIKIAAS 160 LKGI
|
|||||
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .LP3 or .LP32 or .LP33 or :3LP3;style chemicals stick;color identity;select .A:17 or .A:18 or .A:19 or .A:41 or .A:42 or .A:43 or .A:47 or .A:82 or .A:86 or .A:89 or .A:90 or .A:95 or .A:96 or .A:97 or .A:100 or .A:101 or .A:105 or .A:106 or .A:107 or .A:111 or .A:114 or .A:116 or .A:143 or .A:145 or .A:152 or .A:153 or .A:154 or .A:155; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
ALA17
3.025
VAL18
4.222
ILE19
3.855
GLY41
2.890
SER42
2.978
THR43
3.379
LEU47
3.333
PHE82
3.798
LEU86
3.883
LEU89
3.929
ILE90
4.309
PRO95
4.321
CYS96
4.780
PRO97
3.494
|
|||||
Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
Ligand Name: Distearoyl phosphatidic acid | Ligand Info | |||||
Structure Description | GM2-activator Protein crystal structure | PDB:1PUB | ||||
Method | X-ray diffraction | Resolution | 2.51 Å | Mutation | No | [3] |
PDB Sequence |
SSFSWDNCDE
10 GKDPAVIRSL20 TLEPDPIIVP30 GNVTLSVMGS40 TSVPLSSPLK50 VDLVLEKEVA 60 GLWIKIPCTD70 YIGSCTFEHF80 CDVLDMLIPT90 GEPCPEPLRT100 YGLPCHCPFK 110 EGTYSLPKSE120 FVVPDLELPS130 WLTTGNYRIE140 SVLSSSGKRL150 GCIKIAASLK 160 GI
|
|||||
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .3PH or .3PH2 or .3PH3 or :33PH;style chemicals stick;color identity;select .A:15 or .A:16 or .A:17 or .A:20 or .A:22 or .A:27 or .A:35 or .A:37 or .A:39 or .A:40 or .A:41 or .A:45 or .A:51 or .A:53 or .A:55 or .A:66 or .A:72 or .A:98 or .A:103 or .A:104 or .A:109 or .A:114 or .A:137 or .A:139 or .A:141 or .A:143 or .A:151 or .A:152 or .A:153 or .A:155 or .A:157 or .A:159; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
ALA15
3.918
VAL16
4.083
ILE17
3.921
LEU20
3.851
LEU22
3.900
ILE27
3.530
LEU35
4.886
VAL37
3.430
GLY39
4.839
SER40
3.754
THR41
4.731
LEU45
4.914
VAL51
4.579
LEU53
4.037
LEU55
4.028
ILE66
4.887
|
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Crystal structure analysis of phosphatidylcholine-GM2-activator product complexes: evidence for hydrolase activity. Biochemistry. 2005 Oct 18;44(41):13510-21. | ||||
REF 2 | Evidence for lipid packaging in the crystal structure of the GM2-activator complex with platelet activating factor. J Mol Biol. 2004 Sep 10;342(2):585-92. | ||||
REF 3 | Structural analysis of lipid complexes of GM2-activator protein. J Mol Biol. 2003 Aug 22;331(4):951-64. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.